Corbus Pharmaceuticals (NASDAQ: CRBP) furnishes Q3 2025 results release

Rhea-AI Filing Summary

Corbus Pharmaceuticals Holdings, Inc. filed a current report describing that it issued a press release on November 12, 2025 with financial information and operating metrics for its fiscal quarter ended September 30, 2025, along with a discussion of its business outlook. The press release is attached as Exhibit 99.1 and is incorporated by reference.

The company notes that the information provided under Items 2.02 and 7.01, including Exhibit 99.1, is being furnished to the SEC and is not deemed filed for liability purposes under the Exchange Act or automatically incorporated into other securities filings, unless specifically referenced.

8-K Event Classification

3 items: 2.02, 7.01, 9.01

3 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding 8-K Material Events →

Accepted by SEC EDGAR 11/12/2025 - 08:14 AM Learn about SEC filing dates

0001595097false00015950972025-11-122025-11-12

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 12, 2025

CORBUS PHARMACEUTICALS HOLDINGS, INC.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-37348	46-4348039
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
500 River Ridge Drive
Norwood, Massachusetts				02062
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: (617) 963-0100

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.0001 per share		CRBP		The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

Corbus Pharmaceuticals Holdings, Inc. (the “Company”) issued a press release on November 12, 2025, disclosing financial information and operating metrics for its fiscal quarter ended September 30, 2025 and discussing its business outlook. A copy of the Company’s press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 7.01 Regulation FD Disclosure.

See “Item 2.02 Results of Operations and Financial Condition” above.

The information in this Current Report on Form 8-K under Items 2.02 and 7.01, including the information contained in Exhibit 99.1, is being furnished to the Securities and Exchange Commission, and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934, except as shall be expressly set forth by a specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) The following exhibit is furnished with this report:

Exhibit No.		Description
99.1		Press Release issued by Corbus Pharmaceuticals Holdings, Inc. dated November 12, 2025.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

			Corbus Pharmaceuticals Holdings, Inc.
Date:	November 12, 2025	By:	/s/ Yuval Cohen
			Name: Yuval Cohen Title: Chief Executive Officer

FAQ

What did Corbus Pharmaceuticals (CRBP) disclose in this SEC report?

Corbus Pharmaceuticals Holdings, Inc. disclosed that it issued a press release on November 12, 2025 providing financial information, operating metrics, and a business outlook for its fiscal quarter ended September 30, 2025, and furnished that press release as Exhibit 99.1.

Which period does Corbus Pharmaceuticals' latest financial update cover?

The financial information and operating metrics discussed by Corbus Pharmaceuticals Holdings, Inc. in the referenced press release relate to its fiscal quarter ended September 30, 2025.

How is the information in Items 2.02 and 7.01 of this Corbus (CRBP) report treated?

The information provided under Items 2.02 and 7.01, including Exhibit 99.1, is being furnished to the SEC and is not deemed to be filed under Section 18 of the Exchange Act or otherwise subject to those liabilities, nor incorporated into other filings unless expressly referenced.

What exhibits are included with this Corbus Pharmaceuticals current report?

The report includes Exhibit 99.1, which is the press release issued by Corbus Pharmaceuticals Holdings, Inc. dated November 12, 2025, and Exhibit 104, the Cover Page Interactive Data File embedded within the Inline XBRL document.

Who signed this Corbus Pharmaceuticals SEC report?

The report was signed on behalf of Corbus Pharmaceuticals Holdings, Inc. by Yuval Cohen, who is identified as the Chief Executive Officer.

Does this Corbus Pharmaceuticals filing itself contain detailed financial figures?

The filing states that detailed financial information and operating metrics are contained in the press release attached as Exhibit 99.1, rather than being presented directly within the main body of the report.